DLD Asset Management LP Has $2.20 Billion Position in Halozyme Therapeutics, Inc. $HALO

DLD Asset Management LP raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 20.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 30,000,000 shares of the biopharmaceutical company’s stock after purchasing an additional 5,000,000 shares during the quarter. Halozyme Therapeutics accounts for approximately 11.8% of DLD Asset Management LP’s investment portfolio, making the stock its 3rd biggest position. DLD Asset Management LP owned about 25.51% of Halozyme Therapeutics worth $2,200,200,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. Private Advisor Group LLC raised its holdings in Halozyme Therapeutics by 0.8% in the 3rd quarter. Private Advisor Group LLC now owns 23,623 shares of the biopharmaceutical company’s stock valued at $1,733,000 after buying an additional 184 shares during the last quarter. Diversify Advisory Services LLC grew its holdings in Halozyme Therapeutics by 11.7% during the 3rd quarter. Diversify Advisory Services LLC now owns 7,741 shares of the biopharmaceutical company’s stock worth $568,000 after acquiring an additional 812 shares during the period. Vinva Investment Management Ltd grew its stake in Halozyme Therapeutics by 91.0% during the third quarter. Vinva Investment Management Ltd now owns 10,528 shares of the biopharmaceutical company’s stock worth $772,000 after purchasing an additional 5,016 shares during the period. First Trust Advisors LP increased its stake in shares of Halozyme Therapeutics by 1.4% in the 3rd quarter. First Trust Advisors LP now owns 776,411 shares of the biopharmaceutical company’s stock valued at $56,942,000 after acquiring an additional 10,493 shares in the last quarter. Finally, Marietta Investment Partners LLC increased its stake in Halozyme Therapeutics by 1.1% in the third quarter. Marietta Investment Partners LLC now owns 29,151 shares of the biopharmaceutical company’s stock valued at $2,138,000 after purchasing an additional 330 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total transaction of $1,522,400.00. Following the transaction, the chief executive officer owned 708,719 shares in the company, valued at approximately $53,947,690.28. The trade was a 2.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the transaction, the director directly owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. This trade represents a 4.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 62,000 shares of company stock worth $4,545,200 in the last 90 days. Company insiders own 2.90% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $67.37 on Monday. The firm’s fifty day simple moving average is $72.66 and its 200 day simple moving average is $70.72. The stock has a market cap of $7.95 billion, a P/E ratio of 27.06, a price-to-earnings-growth ratio of 0.27 and a beta of 0.98. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89. Halozyme Therapeutics, Inc. has a twelve month low of $47.50 and a twelve month high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The firm had revenue of $451.77 million during the quarter, compared to analysts’ expectations of $446.13 million. During the same period in the previous year, the company earned $1.26 earnings per share. Halozyme Therapeutics’s revenue for the quarter was up 51.6% on a year-over-year basis. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Benchmark boosted their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Finally, Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $78.56.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.